公开(公告)号：US20140353137A1

公开(公告)日：2014-12-04

申请号：US14347052

申请日：2012-09-14

Applicant: Dawei Zhang

Inventor： Dawei Zhang

IPC: B01J20/34 ,  C10B39/00

CPC classification number: B01J20/3416 ,  B01D53/265 ,  C02F1/283 ,  C02F2303/16 ,  C10B1/10 ,  C10B39/00 ,  C10B47/30 ,  C10B53/04 ,  C10B57/02

Abstract: The present invention discloses a dust removing and coding method for an active coke regeneration apparatus. When the active coke regeneration apparatus is operating, the method includes the following: generating two negative pressure regions respectively at a discharge end and a feeding end; sucking out leaked vapour and dust by means of the negative regions; and cooling down the active coke regeneration apparatus by using gas flow generated by the negative pressure. Moreover, the present invention provides a device for implementing the method as described above.

Abstract translation: 本发明公开了一种用于活性焦炭再生装置的除尘和编码方法。 当活性焦炭再生装置运行时，该方法包括以下步骤：在排出端和进料端分别产生两个负压区域; 通过负区域吸出蒸汽和灰尘; 并通过使用由负压产生的气流来冷却活性焦炭再生装置。 此外，本发明提供一种用于实现上述方法的装置。

公开(公告)号：US20140044758A1

公开(公告)日：2014-02-13

申请号：US14112177

申请日：2012-03-02

Applicant: Xiaodong Wang ,  Dawei Zhang ,  Xiaohui Mo ,  Qiulan Lv ,  Zhenjun Wu

Inventor： Xiaodong Wang ,  Dawei Zhang ,  Xiaohui Mo ,  Qiulan Lv ,  Zhenjun Wu

IPC: A61L15/42 ,  A61L15/22

CPC classification number: A61L15/42 ,  A61F13/00008 ,  A61L15/225 ,  A61L15/28 ,  A61L15/46 ,  A61L15/60 ,  A61L2300/404 ,  C08L5/08 ,  C08L1/28

Abstract: A wound dressing with bacteriostatic and hygroscopicity, preparation method therefore, and the use thereof in preparing a product for treating chronic wounds. The dressing comprises chitosan fiber and modified cellulose fiber.

Abstract translation: 具有抑菌和吸湿性的伤口敷料，因此制备方法及其在制备用于治疗慢性伤口的产品中的用途。 敷料包括壳聚糖纤维和改性纤维素纤维。

公开(公告)号：US08574635B2

公开(公告)日：2013-11-05

申请号：US12932018

申请日：2011-02-16

Applicant: Sylvia Lee-Huang ,  Paul L. Huang ,  Philip Lin Huang ,  Dawei Zhang ,  John Z. H. Zhang ,  Young Tae Chang ,  Jae Wook Lee ,  Ju Bao ,  Yongtao Sun

Inventor： Sylvia Lee-Huang ,  Paul L. Huang ,  Philip Lin Huang ,  Dawei Zhang ,  John Z. H. Zhang ,  Young Tae Chang ,  Jae Wook Lee ,  Ju Bao ,  Yongtao Sun

IPC: A01N65/00

CPC classification number: A61K31/7048 ,  A61K31/05 ,  A61K31/155 ,  A61K31/175 ,  A61K31/351 ,  A61K31/366 ,  A61K31/40 ,  A61K31/404 ,  A61K31/427 ,  A61K31/435 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/70 ,  A61K31/7036 ,  A61K36/00 ,  A61K38/28 ,  A61K45/06

Abstract: The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues.

公开(公告)号：US08497269B2

公开(公告)日：2013-07-30

申请号：US13123889

申请日：2009-10-07

Applicant: Andrew Tasker ,  James R. Falsey ,  Robert M. Rzasa ,  Bradley J. Herberich ,  Dawei Zhang

Inventor： Andrew Tasker ,  James R. Falsey ,  Robert M. Rzasa ,  Bradley J. Herberich ,  Dawei Zhang

IPC: C07D487/04 ,  A61K31/50 ,  A01N43/58

CPC classification number: C07D401/12 ,  C07D237/30 ,  C07D237/32 ,  C07D237/34 ,  C07D401/04 ,  C07D403/04 ,  C07D413/04

Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A4, L, R1, R2, R3, R5 and m are as defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, ankylosing spondylitis, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

Abstract translation: 本发明包括一类新的可用于预防和治疗蛋白激酶介导的疾病，包括炎症和相关病症的化合物。 该化合物具有通式I，其中A4，L，R1，R2，R3，R5和m如本文所定义。 本发明还包括药物组合物，其包含一种或多种式I化合物，用于治疗p38地图激酶介导的疾病包括类风湿性关节炎，牛皮癣，慢性阻塞性肺病，强直性脊柱炎，疼痛和其它炎症性疾病的化合物和组合物的用途，如 以及可用于制备式I化合物的中间体和方法。

公开(公告)号：US08101612B2

公开(公告)日：2012-01-24

申请号：US11899363

申请日：2007-09-04

Applicant: Andrew Tasker ,  Dawei Zhang ,  Liping H. Pettus ,  Rob M. Rzasa ,  Kelvin K. C. Sham ,  Shimin Xu ,  Partha Chakrabarti

Inventor： Andrew Tasker ,  Dawei Zhang ,  Liping H. Pettus ,  Rob M. Rzasa ,  Kelvin K. C. Sham ,  Shimin Xu ,  Partha Chakrabarti

IPC: C07D237/30 ,  C07D413/04 ,  A61K31/502 ,  A61K31/5355 ,  A61P29/00 ,  A61P19/02 ,  A61P19/10 ,  A61P17/06 ,  A61P17/00 ,  A61P31/00 ,  A61P31/16 ,  A61P31/22 ,  A61P37/08 ,  A61P21/00 ,  A61P3/10 ,  A61P9/10 ,  A61P33/06

CPC classification number: C07D403/12 ,  C07D237/30 ,  C07D237/34 ,  C07D403/10 ,  C07D413/12 ,  C07D417/10 ,  C07D471/04

Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of p38 kinase mediated diseases and related inflammatory conditions. The compounds have a general Formula II wherein L1, L2, R1a, R1b, R1c, R2, R3, R3a, R4, R5 and p are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

Abstract translation: 本发明包括一类新的可用于预防和治疗p38激酶介导的疾病和相关炎性病症的化合物。 该化合物具有通式II，其中本文定义了L1，L2，R1a，R1b，R1c，R2，R3，R3a，R4，R5和p。 本发明还包括包含一种或多种式I化合物的药物组合物，用于治疗p38激酶介导的疾病（包括类风湿性关节炎，牛皮癣和其它炎症疾病）的这些化合物和组合物的用途，以及可用于制备化合物的中间体和方法 的式

公开(公告)号：US20100179177A1

公开(公告)日：2010-07-15

申请号：US12713360

申请日：2010-02-26

Applicant: Yi Chen ,  Timothy D. Cushing ,  Xiaolin Hao ,  Xiao He ,  Andreas Reichelt ,  Robert M. Rzasa ,  Jennifer Seganish ,  Youngsook Shin ,  Dawei Zhang

Inventor： Yi Chen ,  Timothy D. Cushing ,  Xiaolin Hao ,  Xiao He ,  Andreas Reichelt ,  Robert M. Rzasa ,  Jennifer Seganish ,  Youngsook Shin ,  Dawei Zhang

IPC: A61K31/506 ,  C07D239/42 ,  C07D215/36 ,  A61K31/4709 ,  C07D215/12 ,  A61P19/02 ,  A61P19/00 ,  A61P29/00 ,  A61P37/00 ,  A61P27/02 ,  A61P13/10 ,  A61P17/00 ,  A61P1/00 ,  A61P35/00

CPC classification number: C07D401/12 ,  C07D401/14

Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Abstract translation: 取代的双环杂芳基和含有它们的组合物，用于治疗一般炎症，关节炎，风湿性疾病，骨关节炎，炎性肠病，炎症性眼病，炎症性或不稳定性膀胱病，牛皮癣，皮肤炎症成分的投诉，慢性炎性病症 不限于自身免疫性疾病如系统性红斑狼疮（SLE），重症肌无力，类风湿性关节炎，急性播散性脑脊髓炎，特发性血小板减少性紫癜，多发性硬化症，Sjoegren综合征和自身免疫性溶血性贫血，包括所有形式的超敏反应的过敏症状 包括但不限于白血病，如急性骨髓性白血病（AML）骨髓增生异常综合征（MDS）骨髓增生性疾病（MPD）慢性骨髓性白血病（MPD），介导，依赖或与p110δ活性相关的癌症的方法 （CML）T细胞急性淋巴细胞白血病（T-ALL）B细胞急性淋巴细胞白血病（B-ALL）非霍奇金淋巴瘤（NHL）B细胞淋巴瘤和实体瘤如乳腺癌。

公开(公告)号：US07678738B2

公开(公告)日：2010-03-16

申请号：US12301524

申请日：2007-05-18

Applicant: Dawei Zhang

Inventor： Dawei Zhang

IPC: C01B31/08

CPC classification number: B01J20/3483 ,  B01J20/20 ,  B01J20/3416 ,  C01B32/36 ,  C02F1/283 ,  C02F2303/16

Abstract: A method for treating saturated activated coke comprises the following steps: A) The saturated activated coke is subjected to a dehydration treatment so that the water content in the activated coke is ≦25%; B) The product obtained from step A is dried at a starting temperature of 120° C.-150° C.; C) The product obtained from step B is subjected to dry distillation and the condition of the dry distillation is that: by heating to a final temperature for the drying of 500° C.-600° C. at a speed of 4° C.-10° C./min and maintaining for 10-60 minutes, the organics adsorbed on the surface and in the pores of the activated coke is cracked, volatilized and carbonized; D) The product obtained from step C is activated and the activation condition is that: after heating to 800° C.-950° C. at 2° C.-8° C./min, a stream is supplied, wherein the weight ratio of the activated coke to the stream is 1:0.5-5 and the activation time is 0.5-2 h. The activated coke after several times of treatment can be used as the fuel.

Abstract translation: 一种处理饱和活性焦炭的方法，包括以下步骤：A）对饱和活性焦炭进行脱水处理，使活性焦炭中的水分含量为25％; B）从步骤A得到的产物在起始温度为120℃-150℃下干燥。 C）将从步骤B得到的产物进行干馏，干馏条件为：以4℃的速度加热至500℃-600℃的最终温度。 -10℃/分钟，保持10-60分钟，吸附在表面和活性焦炭孔中的有机物被破裂，挥发和碳化; D）从步骤C获得的产物被活化，活化条件是：在2℃-8℃/分钟加热至800℃-950℃后，供应流，其中重量 活性焦炭与料流的比例为1:0.5-5，活化时间为0.5-2小时。 经过几次处理后的活化焦炭可用作燃料。

公开(公告)号：US20090023761A1

公开(公告)日：2009-01-22

申请号：US12079322

申请日：2008-03-24

Applicant: Yi Chen ,  Timothy D. Cushing ,  Xiaolin Hao ,  Xiao He ,  Andreas Reichelt ,  Robert M. Rzasa ,  Jennifer Seganish ,  Youngsook Shin ,  Dawei Zhang

Inventor： Yi Chen ,  Timothy D. Cushing ,  Xiaolin Hao ,  Xiao He ,  Andreas Reichelt ,  Robert M. Rzasa ,  Jennifer Seganish ,  Youngsook Shin ,  Dawei Zhang

IPC: A61K31/506 ,  A61P17/06 ,  A61P29/00 ,  A61P37/00 ,  A61K31/4709 ,  A61P19/00 ,  C07D401/12 ,  C07D401/14

CPC classification number: C07D401/12 ,  C07D401/14

Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Abstract translation: 取代的双环杂芳基和含有它们的组合物，用于治疗一般炎症，关节炎，风湿性疾病，骨关节炎，炎性肠病，炎症性眼病，炎症性或不稳定性膀胱病，牛皮癣，皮肤炎症成分的投诉，慢性炎性病症 不限于自身免疫疾病如系统性红斑狼疮（SLE），重症肌无力，类风湿性关节炎，急性播散性脑脊髓炎，特发性血小板减少性紫癜，多发性硬化症，Sjoegren综合征和自身免疫性溶血性贫血，包括所有形式的超敏反应的过敏症状 包括但不限于白血病，例如急性骨髓性白血病（AML）骨髓增生异常综合征（MDS）骨髓增生性疾病（MPD）慢性骨髓性白血病（Myeloid Leukem）的介导，依赖于或与p110delta活性相关的癌症的方法 ia（CML）T细胞急性淋巴细胞白血病（T-ALL）B细胞急性淋巴细胞白血病（B-ALL）非霍奇金淋巴瘤（NHL）B细胞淋巴瘤和实体瘤如乳腺癌。

公开(公告)号：US06529750B1

公开(公告)日：2003-03-04

申请号：US09285350

申请日：1999-04-02

Applicant: Dawei Zhang ,  Ji-Fuh Liang ,  Chien-Fu Shih

Inventor： Dawei Zhang ,  Ji-Fuh Liang ,  Chien-Fu Shih

IPC: H03H701

CPC classification number: H01P1/20336 ,  H01P1/20381 ,  Y10S505/70 ,  Y10S505/866

Abstract: The present invention provides for a method and apparatus to control non-adjacent cross-coupling in a micro-strip filter. In instances of weak cross-coupling, such as a filter circuit on a high dielectric constant substrate material (e.g., LaAIO3 with dielectric constant of 24), a closed loop is used to inductively enhance the cross-coupling. The closed loop increases the transmission zero levels. For strong cross-coupling cases, such as a filter circuit on a lower dielectric constant substrate material (e.g., MgO with dielectric constant of 9.6), a capacitive cross-coupling cancellation mechanism is introduced to reduce the cross-coupling. In the latter instance, the transmission zero levels are moved down.

Abstract translation: 本发明提供了一种用于控制微带滤波器中的非相邻交叉耦合的方法和装置。 在弱交叉耦合的情况下，例如高介电常数衬底材料（例如，介电常数为24的LaAlO 3）上的滤波器电路，使用闭环来感应地增强交叉耦合。 闭环增加传输零电平。 对于强交叉耦合情况，例如在较低介电常数衬底材料（例如，介电常数为9.6的MgO）上的滤波器电路，引入电容性交叉耦合消除机制以减少交叉耦合。 在后一种情况下，传输零电平向下移动。

公开(公告)号：US11427559B2

公开(公告)日：2022-08-30

申请号：US16970349

申请日：2019-02-20

Applicant: Dawei Zhang

Inventor： Dawei Zhang

IPC: C07D401/12 ,  A61P35/00

Abstract: The present invention is directed to novel quinoline-3-carbonitriles according to Formula I, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are useful for the treatment of protein kinases mediated diseases and conditions.